NCT05758948Completed
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
To determine somatic and germline pathogenic variants in patients with denovo metastatic breast cancer in order to map the molecular/genetic characteristics of DN- MBC aiming in comprehending the biology and highlighting potential novel treatment options for the disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 101 (estimated)
- First submitted
- 15 Feb 2023
- Start date
- 5 Jul 1998
- Primary completion date
- 7 Oct 2025
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Diseases
- Metastatic breast cancer
- NCT number
- NCT05758948
What you commit to
- Study type: Observational
- Planned participants: 101
- From 5 Jul 1998 to the primary completion date, 7 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inadequate MBC tissue
Who the study is looking for
- Signed informed consent for the provision of the biological material for research purposes
- Diagnosis of de novo MBC (histologically confirmed)
- Age \>18 years
- Blood samples
- Tumor tissue block from at least on disease site, primary (preferably) or metastatic
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Evangelia Moirogiorgou Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.